hydralazine has been researched along with Pulmonary Embolism in 11 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Pulmonary Embolism: Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We employed a canine model of pulmonary embolism, induced by injection of autologous radiolabelled blood clots, to investigate effects of hydralazine and an increase in cardiac output per se on recombinant tissue plasminogen activator-induced thrombolysis." | 7.68 | Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism. ( Chan, SM; Downes, AM; Ducas, J; Gu, SA; Prewitt, RM, 1991) |
| "We employed a canine model of pulmonary embolism, induced by injection of autologous radiolabelled blood clots, to investigate effects of hydralazine and an increase in cardiac output per se on recombinant tissue plasminogen activator-induced thrombolysis." | 3.68 | Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism. ( Chan, SM; Downes, AM; Ducas, J; Gu, SA; Prewitt, RM, 1991) |
| "Hydralazine was the only drug that significantly increased cardiac output (1." | 1.28 | Vasodilator therapy in microembolic porcine pulmonary hypertension. ( McLean, RF; Pearl, RG; Prielipp, RC; Rosenthal, MH, 1990) |
| "Thus, in this canine model of acute pulmonary embolism: 1) VA/Q distributions were moderately impaired accounting for only slight hypoxemia, and 2) pulmonary hypertension was partially reversible by hydralazine and by nitroprusside without associated non-flow-dependent change in VA/Q distributions and arterial oxygenation." | 1.28 | Effects of vasodilators on gas exchange in acute canine embolic pulmonary hypertension. ( Delcroix, M; Leeman, M; Lejeune, P; Mélot, C; Naeije, R, 1990) |
| "Hydralazine was administered in a dose sufficient to double CO." | 1.27 | Pulmonary vascular effects of hydralazine in a canine preparation of pulmonary thromboembolism. ( Ducas, J; Girling, L; Prewitt, RM; Schick, U, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (45.45) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yee, J | 1 |
| Cordasco, EM | 1 |
| Lee, KY | 1 |
| Molloy, DW | 1 |
| Slykerman, L | 1 |
| Prewitt, RM | 3 |
| Bates, ER | 1 |
| Crevey, BJ | 1 |
| Sprague, FR | 1 |
| Pitt, B | 1 |
| Ueno, Y | 1 |
| Kawashima, A | 1 |
| Koike, H | 1 |
| Nishio, S | 1 |
| Lupi-Herrera, E | 1 |
| Furuya, ME | 1 |
| Sandoval, J | 1 |
| Correa, E | 1 |
| Leal, ME | 1 |
| Quesada, A | 1 |
| Palomar, A | 1 |
| Barrios, R | 1 |
| Downes, AM | 1 |
| Gu, SA | 1 |
| Chan, SM | 1 |
| Ducas, J | 2 |
| McLean, RF | 1 |
| Prielipp, RC | 1 |
| Rosenthal, MH | 1 |
| Pearl, RG | 1 |
| Delcroix, M | 1 |
| Mélot, C | 1 |
| Lejeune, P | 1 |
| Leeman, M | 1 |
| Naeije, R | 1 |
| Priebe, HJ | 1 |
| Girling, L | 1 |
| Schick, U | 1 |
11 other studies available for hydralazine and Pulmonary Embolism
| Article | Year |
|---|---|
PGX: Pharmacogenomics During Generation X.
Topics: Anticoagulants; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Heart Failure; H | 2016 |
Pulmonary vascular disease--overview.
Topics: Angiography; Heparin; Humans; Hydralazine; Hypertension, Pulmonary; Lung; Lung Diseases, Obstructive | 1983 |
Effects of hydralazine and nitroprusside on cardiopulmonary function when a decrease in cardiac output complicates a short-term increase in pulmonary vascular resistance.
Topics: Animals; Blood Pressure; Cardiac Output; Dogs; Ferricyanides; Hydralazine; Nitroprusside; Pulmonary | 1983 |
Oral hydralazine therapy for acute pulmonary embolism and low output state.
Topics: Administration, Oral; Aged; Cardiac Output, Low; Female; Hemodynamics; Humans; Hydralazine; Pulmonar | 1981 |
Effect of beraprost sodium, a stable prostacyclin analogue, on pulmonary thromboembolism in mice.
Topics: Administration, Oral; Alprostadil; Animals; Aspirin; Bridged Bicyclo Compounds; Collagen; Diltiazem; | 1995 |
Effect of hydralazine on vascular mechanics in a canine lobar preparation of pulmonary embolism.
Topics: Animals; Blood Gas Analysis; Disease Models, Animal; Dogs; Hemodynamics; Hydralazine; Pulmonary Embo | 1992 |
Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
Topics: Animals; Arteriovenous Shunt, Surgical; Blood Pressure; Cardiac Output; Dogs; Fibrinolysis; Hydralaz | 1991 |
Vasodilator therapy in microembolic porcine pulmonary hypertension.
Topics: Alprostadil; Animals; Ferricyanides; Hemodynamics; Hydralazine; Hypertension, Pulmonary; Infusions, | 1990 |
Effects of vasodilators on gas exchange in acute canine embolic pulmonary hypertension.
Topics: Acute Disease; Alprostadil; Animals; Dogs; Hydralazine; Hypertension, Pulmonary; Nitroprusside; Pulm | 1990 |
Efficacy of vasodilator therapy in canine model of acute pulmonary hypertension.
Topics: Alprostadil; Animals; Coronary Circulation; Disease Models, Animal; Dogs; Female; Heart Ventricles; | 1988 |
Pulmonary vascular effects of hydralazine in a canine preparation of pulmonary thromboembolism.
Topics: Animals; Blood Pressure; Cardiac Output; Disease Models, Animal; Dogs; Hemodynamics; Hydralazine; Hy | 1986 |